Daniel J Zheng1,2,3, Kevin R Krull4, Yan Chen5, Lisa Diller6,7, Yutaka Yasui4, Wendy Leisenring8, Pim Brouwers9, Rebecca Howell10, Jin-Shei Lai11, Lyn Balsamo1,12, Kevin C Oeffinger13, Leslie L Robison4, Gregory T Armstrong4, Nina S Kadan-Lottick1,12. 1. Yale University School of Medicine, New Haven, Connecticut. 2. Boston Children's Hospital, Boston, Massachusetts. 3. Boston Medical Center, Boston, Massachusetts. 4. St. Jude Children's Research Hospital, Memphis, Tennessee. 5. School of Public Health, University of Alberta, Edmonton, Alberta, Canada. 6. Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts. 7. Harvard Medical School, Boston, Massachusetts. 8. Fred Hutchinson Cancer Research Center, Seattle, Washington. 9. National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland. 10. The University of Texas MD Anderson Cancer Center, Houston, Texas. 11. Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 12. Yale Comprehensive Cancer Center, New Haven, Connecticut. 13. Duke Cancer Institute, Durham, North Carolina.
Abstract
BACKGROUND: Neuroblastoma survivors may be at elevated risk for psychological impairments because of their young age at diagnosis and neurotoxic treatment, but this is not well described. METHODS: A total of 859 ≥5-year survivors of neuroblastoma younger than 18 years (diagnosed in 1970-1999), who had a median age at diagnosis of 0.8 years (range: 0.0-7.3 years) and a median follow-up of 13.3 years (range: 8.0-17.9 years), were compared with 872 siblings of childhood cancer survivors who were younger than 18 years with the parent-reported Behavior Problem Index (BPI) for psychological functioning. Age- and sex-adjusted multivariate log-binomial models were used to identify factors associated with impairment in BPI domains (scores worse than the sibling 10th percentile). The impact of psychological impairment on educational outcomes was examined among survivors. RESULTS: Compared with siblings, neuroblastoma survivors had an increased prevalence of impairment in the domains of anxiety/depression (19% vs 14%; P = .003), headstrong behavior (19% vs 13%; P < .001), attention deficits (21% vs 13%; P < .001), peer conflict/social withdrawal (26% vs 17%; P < .001), and antisocial behavior (16% vs 12%; P = .01). Common treatment exposures (vincristine, cisplatin, and retinoic acid) were not associated with impairment. Having 2 or more chronic health conditions predicted impairment in 4 domains (P < .001). Specifically, pulmonary disease predicted impairment in all 5 domains (P ≤ .004). Endocrine disease (P ≤ .004) and peripheral neuropathy (P ≤ .02) each predicted impairment in 3 domains. Psychological impairment was associated with special education service usage and educational attainment less than college. CONCLUSIONS: Neuroblastoma survivors are at elevated risk for psychological impairment, which is associated with special education service usage and lower adult educational attainment. Those with chronic health conditions may represent a high-risk group for targeted screening and intervention. Cancer 2018.
BACKGROUND:Neuroblastoma survivors may be at elevated risk for psychological impairments because of their young age at diagnosis and neurotoxic treatment, but this is not well described. METHODS: A total of 859 ≥5-year survivors of neuroblastoma younger than 18 years (diagnosed in 1970-1999), who had a median age at diagnosis of 0.8 years (range: 0.0-7.3 years) and a median follow-up of 13.3 years (range: 8.0-17.9 years), were compared with 872 siblings of childhood cancer survivors who were younger than 18 years with the parent-reported Behavior Problem Index (BPI) for psychological functioning. Age- and sex-adjusted multivariate log-binomial models were used to identify factors associated with impairment in BPI domains (scores worse than the sibling 10th percentile). The impact of psychological impairment on educational outcomes was examined among survivors. RESULTS: Compared with siblings, neuroblastoma survivors had an increased prevalence of impairment in the domains of anxiety/depression (19% vs 14%; P = .003), headstrong behavior (19% vs 13%; P < .001), attention deficits (21% vs 13%; P < .001), peer conflict/social withdrawal (26% vs 17%; P < .001), and antisocial behavior (16% vs 12%; P = .01). Common treatment exposures (vincristine, cisplatin, and retinoic acid) were not associated with impairment. Having 2 or more chronic health conditions predicted impairment in 4 domains (P < .001). Specifically, pulmonary disease predicted impairment in all 5 domains (P ≤ .004). Endocrine disease (P ≤ .004) and peripheral neuropathy (P ≤ .02) each predicted impairment in 3 domains. Psychological impairment was associated with special education service usage and educational attainment less than college. CONCLUSIONS:Neuroblastoma survivors are at elevated risk for psychological impairment, which is associated with special education service usage and lower adult educational attainment. Those with chronic health conditions may represent a high-risk group for targeted screening and intervention. Cancer 2018.
Authors: Wendy M Leisenring; Ann C Mertens; Gregory T Armstrong; Marilyn A Stovall; Joseph P Neglia; Jennifer Q Lanctot; John D Boice; John A Whitton; Yutaka Yasui Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: L E Cohen; J H Gordon; E Y Popovsky; S Gunawardene; E Duffey-Lind; L E Lehmann; L R Diller Journal: Bone Marrow Transplant Date: 2014-01-20 Impact factor: 5.483
Authors: Annemieke I Buizer; Leo M J de Sonneville; Marry M van den Heuvel-Eibrink; Anjo J P Veerman Journal: Pediatr Blood Cancer Date: 2005-09 Impact factor: 3.167
Authors: Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: Med Pediatr Oncol Date: 2002-04
Authors: Melissa M Hudson; Ann C Mertens; Yutaka Yasui; Wendy Hobbie; Hegang Chen; James G Gurney; Mark Yeazel; Christopher J Recklitis; Neyssa Marina; Leslie R Robison; Kevin C Oeffinger Journal: JAMA Date: 2003-09-24 Impact factor: 157.335
Authors: Ellen M Lavoie Smith; Clare Kuisell; Grace A Kanzawa-Lee; Celia M Bridges; Paola Alberti; Guido Cavaletti; Rima Saad; Susanna Park Journal: Lancet Haematol Date: 2020-05 Impact factor: 18.959
Authors: Carmen L Wilson; Tara M Brinkman; Cathleen Cook; Sujuan Huang; Geehong Hyun; Daniel M Green; Wayne L Furman; Nickhill Bhakta; Matthew J Ehrhardt; Matthew J Krasin; Leslie L Robison; Kirsten K Ness; Melissa M Hudson Journal: Cancer Date: 2020-01-10 Impact factor: 6.860
Authors: Cara F Levitch; Benjamin Malkin; Lauren Latella; Whitney Guerry; Sharon L Gardner; Jonathan L Finlay; Stephen A Sands Journal: Neurooncol Pract Date: 2021-05-18
Authors: Pamela S Hinds; Laura C Pinheiro; Molly McFatrich; Mia Waldron; Justin N Baker; Catriona Mowbray; Scott H Maurer; Yao Cheng; Bryce B Reeve; Jichuan Wang Journal: Pediatr Blood Cancer Date: 2021-12-06 Impact factor: 3.838
Authors: Nina S Kadan-Lottick; Daniel J Zheng; Mingjuan Wang; Michael W Bishop; Deo Kumar Srivastava; Wilhelmenia L Ross; Rozalyn L Rodwin; Kirsten K Ness; Todd M Gibson; Sheri L Spunt; Mehmet Fatih Okcu; Wendy M Leisenring; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: J Cancer Surviv Date: 2022-01-21 Impact factor: 4.062
Authors: Ellen van der Plas; Weiyu Qiu; Brian J Nieman; Yutaka Yasui; Qi Liu; Stephanie B Dixon; Nina S Kadan-Lottick; Christopher B Weldon; Brent R Weil; Lisa M Jacola; Todd M Gibson; Wendy Leisenring; Kevin Oeffinger; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: J Natl Cancer Inst Date: 2021-05-04 Impact factor: 13.506